Griseofulvin

Griseofulvin is a systemic antifungal medication that has been used for decades to treat dermatophyte infections, commonly known as ringworm, in dogs and other animals. This medication represents one of the oldest and most established treatments for fungal infections affecting the skin, hair, and nails in veterinary medicine. While griseofulvin was historically the FDA-approved systemic antifungal for veterinary use, its role has evolved as newer antifungal agents have become available. Nevertheless, it remains an important therapeutic option for treating dermatophytosis in canine patients when prescribed and monitored appropriately by a veterinarian.

The mechanism of action of griseofulvin involves disrupting the mitotic spindle of fungal cells by interacting with polymerized microtubules in susceptible dermatophyte organisms. This interference prevents proper cell division and leads to the production of multinucleate fungal cells that cannot function normally. Additionally, griseofulvin inhibits nucleic acid synthesis and interferes with the formation of hyphal cell wall material, causing distortion, irregular swelling, and spiral curling of the fungal hyphae. It is important to understand that griseofulvin is fungistatic rather than fungicidal, meaning it prevents fungal growth rather than directly killing the organisms, except in young, actively dividing cells. This distinction means that treatment must continue long enough for the infected tissue to be replaced by healthy, drug-containing tissue.

Griseofulvin is available in several oral formulations for administration to dogs, including tablets and oral liquid suspensions. The tablets come in two particle sizes: microsized and ultramicrosized, with the ultramicrosized particles having better bioavailability due to improved absorption. The medication is typically administered once daily, although the dose may be divided into twice-daily administration to reduce gastrointestinal side effects. A critical aspect of griseofulvin administration is that it should always be given with a fatty meal, as high-fat foods significantly enhance the gastrointestinal absorption of the medication. Foods such as cheese, butter, cream, or corn oil can be used to improve drug uptake. The duration of treatment often extends for several weeks to months, depending on the severity and location of the infection.

The safety profile of griseofulvin in dogs is generally acceptable when the medication is used at proper dosages under veterinary supervision, although side effects can occur. Because griseofulvin is a liver microsomal enzyme inducer, dogs receiving this medication should have their liver function monitored periodically, especially during extended treatment courses. Veterinary guidance is essential for determining appropriate dosing based on the dog's weight and condition, as well as for monitoring treatment response and potential adverse effects. Completing the full course of treatment is crucial for achieving mycological cure, as stopping medication prematurely when clinical signs resolve can lead to recurrence of the infection.

Griseofulvin is primarily indicated for the treatment of dermatophytosis, commonly known as ringworm, in dogs. Dermatophyte infections are caused by a group of fungi that have the ability to invade and grow in keratinized tissues such as skin, hair, and nails. The dermatophyte organisms that griseofulvin effectively targets include species of Microsporum, Trichophyton, and Epidermophyton. These fungal infections are relatively common in dogs and can cause significant discomfort, hair loss, and skin lesions. Griseofulvin has been a first-line treatment option for ringworm for many years, although newer antifungal agents are now often preferred in some clinical situations due to their improved safety profiles or efficacy.

The primary use of griseofulvin centers on treating superficial fungal infections that affect the epidermis, hair follicles, and nail beds. In dogs, the most common dermatophyte is Microsporum canis, followed by Trichophyton mentagrophytes. Clinical signs of dermatophytosis in dogs typically include circular patches of hair loss, scaling, crusting, and sometimes redness or inflammation of the skin. The infected hairs become brittle and break easily. While some ringworm lesions may be localized and potentially treatable with topical therapy alone, most cases require systemic treatment with oral medication like griseofulvin to achieve complete resolution. The medication works by concentrating in keratin precursor cells, making new hair and skin growth resistant to fungal invasion.

Beyond its primary indication for typical ringworm presentations, griseofulvin may be prescribed for various dermatophyte-related conditions in dogs. These include fungal infections of the claws (onychomycosis), widespread or generalized dermatophytosis affecting multiple body areas, and cases where topical therapy has proven insufficient. The medication is effective only against dermatophyte fungi and has no activity against other types of fungal organisms, yeast infections, or bacterial infections. This specificity means accurate diagnosis through fungal culture or other diagnostic methods is important before initiating therapy. Veterinarians may also consider griseofulvin for dogs in multi-pet households where ringworm transmission is a concern, as environmental decontamination combined with systemic treatment helps prevent spread between animals and to humans.

Several factors influence when griseofulvin is selected over alternative antifungal treatments. The medication may be chosen when cost is a significant consideration, as it is generally less expensive than some newer antifungal options. However, the selection process also considers the dog's overall health status, particularly liver function, as griseofulvin requires hepatic metabolism and can affect liver enzymes. In cases where dogs cannot tolerate newer azole antifungals or when these medications are contraindicated, griseofulvin provides an alternative therapeutic approach. The veterinarian will weigh factors such as the extent and duration of infection, the dog's age and health status, concurrent medications, and owner compliance when determining the most appropriate treatment choice.

It is worth noting that while griseofulvin remains an effective treatment for dermatophytosis, its use has declined somewhat in recent years as medications like itraconazole and terbinafine have become more commonly prescribed for ringworm in dogs. These newer agents may offer advantages in terms of dosing convenience, side effect profiles, or efficacy in certain situations. Nevertheless, griseofulvin continues to have a place in veterinary medicine as a proven antifungal option, particularly when used with appropriate monitoring and in suitable patient populations. The decision regarding which antifungal to use should always be made by the veterinarian based on the individual dog's circumstances and needs.

The dosing of griseofulvin in dogs must be determined by a veterinarian based on the individual patient's weight, the specific formulation being used, and the nature of the infection being treated. Because dogs vary dramatically in size from tiny toy breeds weighing just a few pounds to giant breeds exceeding one hundred pounds, accurate weight measurement is critical for proper dosing. The veterinarian will calculate the appropriate dose using established guidelines while considering any factors that might affect drug metabolism or tolerance in the individual patient. Dog owners should never attempt to determine dosing on their own or adjust the prescribed dose without veterinary guidance.

General dosing guidelines for griseofulvin in dogs typically range around 25-50 mg per kilogram of body weight, administered orally once daily. However, this dosing can vary significantly depending on the particle size of the formulation being used. Microsized griseofulvin and ultramicrosized griseofulvin are not interchangeable at the same dose, as the ultramicrosized form has improved bioavailability and requires a lower dose to achieve therapeutic blood levels. If a dog is switching from one formulation to another, the veterinarian must recalculate the appropriate dose. Some treatment protocols may divide the daily dose into two administrations given every twelve hours, which may help reduce gastrointestinal side effects in some dogs. The medication should always be administered according to the specific instructions provided by the prescribing veterinarian.

Treatment duration with griseofulvin is typically extended, often lasting several weeks to months depending on the severity and location of the fungal infection. Superficial skin infections may clear more quickly than nail infections, which require new nail growth to replace infected tissue. A common approach is to continue treatment until the dog has been culture-negative for fungal organisms, rather than simply stopping when visible clinical signs resolve. Prematurely discontinuing treatment is one of the most common reasons for treatment failure and recurrence of infection. The veterinarian will schedule follow-up appointments to assess treatment response and perform fungal cultures to determine when therapy can be safely discontinued.

Proper administration of griseofulvin is essential for optimal therapeutic results. The medication should always be given with a meal, preferably one containing fat, as this significantly enhances absorption from the gastrointestinal tract. Suitable fatty foods that can be given with the medication include cheese, butter, cream, or a small amount of corn oil mixed with the dog's regular food. Giving griseofulvin on an empty stomach results in poor absorption and may reduce the effectiveness of treatment. For dogs receiving the tablet form, the medication can be given directly by mouth followed by food, or hidden in a small amount of fatty food. Liquid suspension forms should be measured carefully using the provided measuring device and administered as directed. Some liquid formulations may require shaking before use.

If a dose of griseofulvin is missed, dog owners should give the medication as soon as they remember, unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. It is important never to give a double dose to make up for a missed dose, as this could increase the risk of side effects. If multiple doses are missed or if there is confusion about the dosing schedule, the owner should contact their veterinarian for guidance. For dogs receiving twice-daily dosing, if a dose is missed by less than six hours, it may be given late; if more than six hours have passed, it is generally advisable to skip that dose and continue with the regular schedule.

Completing the full prescribed course of griseofulvin treatment is critically important for achieving a cure and preventing recurrence. Fungal infections like ringworm can appear to resolve clinically before the organisms are completely eliminated, leading owners to mistakenly stop treatment early. However, the infection is likely to return if treatment is discontinued prematurely, and there is also concern about potentially contributing to antifungal resistance. The veterinarian will determine the appropriate duration of therapy and schedule fungal cultures or other follow-up testing to confirm that the infection has been fully eradicated before stopping medication. Dog owners should continue giving the medication exactly as prescribed until told by the veterinarian that treatment is complete.

Griseofulvin is generally well tolerated by dogs when administered at appropriate dosages under veterinary supervision, with most dogs completing their treatment course without experiencing significant adverse effects. However, like all medications, griseofulvin has the potential to cause side effects, and dog owners should be aware of what to watch for during treatment. Monitoring for any changes in the dog's behavior, appetite, or physical condition helps ensure that any problems are identified and addressed promptly. The veterinarian may also recommend periodic blood testing to monitor for potential effects on the liver or bone marrow during extended treatment courses.

The most commonly observed side effects of griseofulvin in dogs involve the gastrointestinal system. These may include nausea, vomiting, diarrhea, and decreased appetite. These digestive disturbances are often mild and may resolve on their own as the dog's system adjusts to the medication. Administering griseofulvin with a fatty meal as directed can help minimize gastrointestinal upset. If vomiting or diarrhea becomes persistent or severe, or if the dog refuses to eat, the veterinarian should be contacted, as these signs may indicate the need to adjust the dose, switch to a different medication, or investigate for other underlying problems. Dividing the daily dose into two smaller doses given twelve hours apart may also help reduce gastrointestinal side effects in some dogs.

Moderate side effects that may occur with griseofulvin use in dogs include effects on the liver and changes in blood cell counts. Griseofulvin is metabolized by the liver and is a microsomal enzyme inducer, which means it can affect liver function and the metabolism of other drugs. Elevated liver enzyme values may be observed on blood tests, indicating hepatic stress. Signs of liver problems in dogs may include yellowing of the eyes or gums (jaundice), dark urine, vomiting, lethargy, and decreased appetite. Dogs with pre-existing liver disease should generally not receive griseofulvin, and periodic monitoring of liver enzymes is recommended during treatment, especially for extended courses. Additionally, griseofulvin can affect bone marrow function, potentially leading to decreased production of blood cells.

Serious side effects requiring immediate veterinary attention are uncommon but can occur. Severe allergic reactions may manifest as facial swelling, hives, difficulty breathing, or collapse. Bone marrow suppression can lead to neutropenia (low white blood cell count), which increases susceptibility to infection, or anemia (low red blood cell count). Signs of bone marrow problems may include unusual tiredness, weakness, pale gums, fever, or increased susceptibility to infections. Neurological side effects including ataxia (uncoordinated movement), depression, or behavioral changes have been reported, particularly in cats, and may occasionally occur in dogs. If any of these serious symptoms develop, the medication should be stopped immediately and emergency veterinary care should be sought.

Some rare but notable side effects of griseofulvin warrant awareness. The medication can cause increased sensitivity to sunlight (photosensitization), making the dog's skin more prone to sunburn. Dogs receiving griseofulvin should avoid excessive sun exposure, particularly those with light-colored or thin coats. Griseofulvin has teratogenic properties, meaning it can cause birth defects in developing fetuses, and should never be given to pregnant dogs. The medication can also affect sperm production in male dogs, making it unsuitable for breeding animals. If any unusual symptoms develop during griseofulvin treatment, owners should stop the medication and contact their veterinarian immediately. The veterinarian may recommend blood tests to evaluate liver function and blood cell counts, and can determine whether treatment should be continued, modified, or changed to an alternative antifungal medication.

Griseofulvin is contraindicated in dogs with known hypersensitivity or allergic reactions to the medication or any of its components. Dogs that have previously experienced adverse reactions to griseofulvin should not receive the drug again, as subsequent exposures could result in more severe allergic responses. Because griseofulvin is derived from Penicillium species (the same genus that produces penicillin), there is potential for cross-reactivity in dogs with penicillin allergies, although this is not definitively established. Any history of drug allergies should be disclosed to the veterinarian so that appropriate precautions can be taken and alternative treatments considered if necessary.

Significant liver dysfunction represents a major contraindication for griseofulvin use in dogs. Because the medication is extensively metabolized by the liver and is a hepatic microsomal enzyme inducer, dogs with liver disease may not be able to process the drug safely. Pre-existing liver problems can be worsened by griseofulvin administration, and impaired liver function may also result in altered drug metabolism, leading to either inadequate therapeutic levels or toxic accumulation. Dogs with known hepatic insufficiency, elevated liver enzymes, or any condition affecting liver function should not receive griseofulvin. The veterinarian may perform liver function tests before starting treatment and may recommend alternative antifungal medications for dogs with compromised hepatic health.

Griseofulvin should not be used in pregnant dogs due to its teratogenic effects, which can cause severe birth defects in developing puppies. The medication can cross the placenta and interfere with fetal development, particularly affecting the skeletal system and causing malformations. Similarly, griseofulvin is not recommended for nursing dogs, as the drug may be excreted in milk and could affect nursing puppies. Dogs intended for breeding should not receive griseofulvin, as the medication can decrease sperm production in males and may affect fertility. Female dogs should not be bred during treatment and for some time afterward. Puppies younger than twelve weeks of age should not receive griseofulvin due to their immature liver function and increased susceptibility to adverse effects.

Other medical conditions may preclude the safe use of griseofulvin in dogs. Dogs with bone marrow disorders or conditions that affect blood cell production should not receive this medication due to the risk of bone marrow suppression. Immune-compromised dogs may be at greater risk for adverse effects and may require alternative treatment approaches. Dogs with systemic lupus erythematosus or similar autoimmune conditions may also be poor candidates for griseofulvin therapy. Severely debilitated or dehydrated dogs should have their general condition stabilized before initiating antifungal therapy. It is essential that dog owners provide the veterinarian with a complete medical history, including all current medications, supplements, and known health conditions, so that contraindications can be identified and the safest and most effective treatment plan can be developed.

Informing the veterinarian about all medications, supplements, and products the dog is currently receiving is essential before starting griseofulvin therapy. Drug interactions can significantly affect both the efficacy and safety of treatment, potentially leading to treatment failure or increased risk of toxicity. Because griseofulvin is a hepatic microsomal enzyme inducer, it has the potential to affect the metabolism of many other drugs, either increasing or decreasing their effectiveness. The veterinarian needs a complete picture of the dog's medication regimen to identify potential interactions and make appropriate adjustments or alternative recommendations.

Griseofulvin has several significant interactions with commonly used medications in veterinary medicine. The most important interactions involve drugs that affect or are affected by liver enzyme activity. Barbiturates, including phenobarbital, can decrease the absorption and antifungal activity of griseofulvin, potentially reducing its effectiveness. At the same time, griseofulvin can increase the metabolism of certain drugs, making them less effective. Cyclosporine, an immunosuppressant used in dogs for immune-mediated conditions and allergies, may have decreased effectiveness when given with griseofulvin. Coumarin anticoagulants (blood thinners) may also be affected, with griseofulvin potentially decreasing their anticoagulant effect. Dogs on anticoagulant therapy may need dose adjustments and more frequent monitoring of clotting times during griseofulvin treatment.

Certain supplements and dietary factors can affect griseofulvin absorption and effectiveness. As previously discussed, fat in the diet enhances griseofulvin absorption, so the medication should be given with fatty food. Conversely, drugs or conditions that reduce gastric acid may decrease absorption. While many common supplements used in dogs, such as joint supplements, probiotics, or fish oil, are not known to have significant interactions with griseofulvin, the veterinarian should still be informed of their use. Some herbal supplements may have hepatotoxic potential or may affect liver enzyme activity, potentially compounding the effects of griseofulvin on the liver. The timing of medication administration may also be important, and the veterinarian can provide guidance on the optimal schedule for giving griseofulvin in relation to other medications and meals.

Monitoring during griseofulvin therapy includes watching for signs of drug interactions as well as direct adverse effects. If the dog is receiving other medications metabolized by the liver, the veterinarian may recommend more frequent blood testing to assess liver function and monitor drug levels if applicable. Signs that a drug interaction may be occurring include unexpected changes in the dog's response to either griseofulvin or concurrent medications, development of new symptoms, or changes in blood test results. Bone marrow suppression is a particular concern when griseofulvin is combined with other medications that can affect blood cell production. If any concerning signs develop, dog owners should contact their veterinarian promptly. Adjustments to the treatment plan, including dose modifications, medication timing changes, or switching to alternative antifungal agents, may be necessary to ensure safe and effective therapy.

Several general precautions should be observed when griseofulvin is prescribed for dogs. Accurate weight measurement is essential for proper dosing, as both underdosing (which may result in treatment failure) and overdosing (which increases the risk of toxicity) can have significant consequences. Dog owners should follow the veterinarian's dosing instructions exactly and use appropriate measuring devices for liquid formulations. The medication should always be given with food containing fat to ensure optimal absorption. Regular follow-up appointments with the veterinarian are important for monitoring treatment response, assessing for adverse effects, and determining when the infection has been adequately treated through negative fungal cultures.

While breed-specific sensitivities to griseofulvin have not been well documented in dogs as they have in some cat breeds, certain canine populations may require additional caution. Dogs with the MDR1 (ABCB1) gene mutation, which is found in many herding breeds including Collies, Australian Shepherds, Shetland Sheepdogs, and related breeds, may have altered drug metabolism for some medications. While griseofulvin is not a primary drug of concern for MDR1-affected dogs in the way that ivermectin and some other drugs are, veterinarians may still exercise caution when prescribing any medication to dogs known or suspected to carry this mutation. Genetic testing is available for dogs of at-risk breeds. Brachycephalic breeds and dogs with known hepatic sensitivities should also be monitored carefully.

Safe handling of griseofulvin is important for protecting both the dog and human family members. Pregnant women should not handle griseofulvin tablets or give the medication to dogs, as the drug is teratogenic and can be absorbed through the skin. If handling is necessary, pregnant women should wear gloves and wash hands thoroughly afterward. Crushed or split tablets can create dust that should not be inhaled. The medication should be stored in its original child-resistant container, in a location inaccessible to children and pets. Flavored formulations may be attractive to dogs and could result in accidental overdose if left within reach. Any unused medication should be disposed of properly through a veterinary drug take-back program or according to local guidelines for pharmaceutical disposal.

Monitoring during griseofulvin treatment should include observation for both efficacy and adverse effects. Owners should watch for improvement in the fungal infection, including resolution of skin lesions, regrowth of hair, and improvement in the condition of affected nails. At the same time, monitoring for side effects such as gastrointestinal upset, changes in appetite, lethargy, or any unusual symptoms is important. The veterinarian may recommend periodic blood testing to evaluate liver enzyme levels and complete blood counts, particularly during extended treatment courses. Any concerning changes should be reported to the veterinarian promptly. Fungal cultures should be performed to confirm that the infection has been eliminated before discontinuing treatment.

Special populations of dogs require particular consideration when griseofulvin is prescribed. Geriatric dogs may have decreased liver and kidney function, potentially affecting drug metabolism and increasing the risk of adverse effects. Puppies under twelve weeks of age should not receive griseofulvin due to their immature hepatic systems. Immunocompromised dogs, including those with concurrent diseases or those receiving immunosuppressive medications, may be at increased risk for adverse effects and may require closer monitoring or alternative treatments. Dogs with chronic conditions requiring ongoing medication may need additional evaluation for potential drug interactions. Working and performance dogs may need consideration of how treatment schedules fit with their activities. In all cases, the decision to use griseofulvin should be made by the veterinarian after careful consideration of the individual dog's circumstances and needs.

Proper storage of griseofulvin is essential for maintaining the medication's stability and effectiveness throughout the treatment course. Tablets and capsules should be stored at room temperature, ideally between 59°F and 86°F (15°C and 30°C), in a location away from excessive heat, moisture, and direct light. The bathroom medicine cabinet is often not an ideal storage location due to humidity from showers and baths. A cool, dry cabinet or drawer away from heat sources such as stoves, radiators, or sunny windowsills is preferable. The medication should be kept in its original container with the lid tightly closed to protect it from moisture and light exposure. Expiration dates should be checked regularly, and expired medication should not be used.

Liquid formulations of griseofulvin, such as oral suspensions, may have specific storage requirements that differ from tablets. Some liquid formulations require refrigeration while others should be stored at room temperature; the pharmacist's instructions or the product label should be followed for the specific formulation dispensed. Liquid suspensions typically need to be shaken well before each use to ensure uniform distribution of the medication throughout the liquid. These formulations may have shorter expiration periods after opening compared to tablets, and any unused portion should be discarded according to the pharmacist's instructions or after the indicated period. The measuring device provided with the suspension should be used for accurate dosing and should be cleaned after each use.

Safety considerations for storing griseofulvin in households with dogs and other pets are particularly important. Because some griseofulvin formulations, especially those compounded for veterinary use, may be flavored to improve palatability, they can be attractive to dogs and may be eagerly consumed if accessible. Accidental ingestion of multiple doses could result in overdose and toxicity. The medication should always be stored in a secure location that pets cannot access, such as a high cabinet, a locked drawer, or a closed medicine cabinet. Child-resistant containers should be used and kept properly closed. When giving doses, only the amount needed for that dose should be removed from the container, and the container should be immediately returned to secure storage. Any spilled medication should be cleaned up promptly.

Proper disposal of griseofulvin is important for protecting both the environment and preventing accidental exposure. Unused or expired medication should never be flushed down the toilet or poured down the drain, as this can contaminate water supplies. Many communities have drug take-back programs that accept unused medications for safe disposal; veterinary clinics may also accept returned medications. If no take-back option is available, the FDA recommends mixing the medication with an undesirable substance such as coffee grounds or cat litter, sealing it in a container, and disposing of it in household trash with personal information removed from the label. Griseofulvin packaging, including empty bottles, should also be disposed of properly with labels removed or obscured. Any questions about proper disposal can be directed to the veterinarian or pharmacist.

The majority of dog breeds tolerate griseofulvin well when the medication is prescribed at appropriate doses and administered according to veterinary instructions. Unlike some other medications where specific breed sensitivities are well documented, griseofulvin does not have extensively reported breed-specific adverse reactions in dogs similar to those seen in certain cat breeds. However, this does not mean that breed considerations should be entirely dismissed. Individual variation in drug metabolism exists within and across breeds, and veterinarians may take breed factors into account when developing treatment plans, particularly for dogs known to have sensitivities to other medications or those belonging to breeds with documented genetic variations affecting drug handling.

Herding breed dogs carrying the MDR1 (ABCB1) gene mutation warrant consideration when any medication is prescribed. Breeds commonly affected by this mutation include Collies (rough and smooth coated), Australian Shepherds, Shetland Sheepdogs, Old English Sheepdogs, English Shepherds, Border Collies, Long-haired Whippets, Silken Windhounds, and mixed breeds with herding dog heritage. The MDR1 mutation affects a protein that normally pumps certain drugs out of brain cells, and dogs with this mutation may have increased sensitivity to various medications. While griseofulvin is not a primary drug of concern for MDR1-affected dogs in the same way that ivermectin at higher doses is, the veterinarian may still recommend caution and careful monitoring. Genetic testing is available to identify dogs carrying the mutation, and owners of at-risk breeds may wish to have their dogs tested before receiving any medications that could potentially be affected.

Size considerations are particularly important when dosing griseofulvin in dogs, given the enormous range in body weights across breeds. Toy breeds weighing only a few pounds require precise dosing and often need formulations that can be accurately divided or measured for their small body size. Compounded liquid formulations may be helpful for achieving accurate doses in very small dogs. Conversely, giant breeds may require large numbers of tablets to achieve appropriate doses, and the veterinarian may need to consider cost and practicality when developing treatment plans for these dogs. The difference in body composition and metabolism between very small and very large dogs may also affect drug distribution and elimination, although specific adjustments are typically not required beyond weight-based dosing.

Age-related considerations apply across all breeds when using griseofulvin. Puppies younger than twelve weeks should not receive this medication due to their immature liver function and increased susceptibility to adverse effects. Young dogs may metabolize medications differently than adults, and careful monitoring is advisable even in puppies old enough to receive griseofulvin. At the other end of the age spectrum, senior dogs may have decreased liver and kidney function that affects drug metabolism. The definition of senior varies by breed size, with large and giant breeds considered geriatric at younger ages than small breeds. Older dogs may require dose adjustments or more frequent monitoring during griseofulvin therapy. The veterinarian will consider the individual dog's age, size, breed, and overall health status when determining the most appropriate treatment approach for fungal infections.

Several alternative systemic antifungal medications are available for treating dermatophytosis in dogs, and veterinarians may choose among these based on various factors including efficacy, safety profile, cost, and individual patient characteristics. Itraconazole (Sporanox, Itrafungol) is a triazole antifungal that has become a preferred treatment for ringworm in many cases due to its broad-spectrum antifungal activity, relatively favorable side effect profile, and the availability of pulse-dosing protocols that can reduce treatment costs. Itraconazole is effective against the same dermatophyte organisms as griseofulvin and additionally has activity against systemic fungal infections such as blastomycosis, histoplasmosis, and cryptococcosis. Terbinafine (Lamisil) is an allylamine antifungal that has gained popularity for treating dermatophytosis in dogs and cats, offering good efficacy with a generally favorable safety profile.

Other antifungal medications that may be used in dogs include ketoconazole (Nizoral) and fluconazole. Ketoconazole is an older azole antifungal that was once widely used but has largely been supplanted by itraconazole due to concerns about efficacy and potential for adverse effects, particularly hepatotoxicity and hormonal effects. However, ketoconazole remains a cost-effective option and is still used in some situations, particularly for Malassezia yeast infections. Fluconazole is primarily used for systemic fungal infections rather than dermatophytosis, as it has relatively poor activity against dermatophyte organisms compared to other options. Newer azole antifungals such as voriconazole and posaconazole are available but are generally reserved for resistant or refractory fungal infections due to their higher cost and limited veterinary experience.

Complementary approaches to treating dermatophytosis often include topical antifungal therapy alongside systemic medication. Lime sulfur dips, miconazole-chlorhexidine shampoos, and enilconazole rinses are commonly used topical treatments that can help reduce environmental contamination and speed resolution of skin lesions. Environmental decontamination is also an important component of managing ringworm, particularly in multi-pet households, as dermatophyte spores can persist in the environment and cause reinfection. The veterinarian may recommend a comprehensive treatment protocol that includes both systemic and topical antifungal therapy along with environmental cleaning measures. Importantly, any changes to the treatment plan or switching between antifungal medications should only be done under veterinary guidance, as different medications have different dosing requirements, side effect profiles, and drug interaction potentials.